Document is current
Any future updates will be listed below
-
Authors
Ranzinger, David https://orcid.org/0009-0006-1337-3836
Eyerich, Kilian https://orcid.org/0000-0003-0094-2674
-
Funding
Funding for this research was provided by:
Universitätsklinikum Freiburg
- License Information
-
More Information
Article History
Accepted: 16 April 2025
First Online: 6 May 2025
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. This research received no specific funding from public, commercial, or non-profit organizations.
: Kilian Eyerich reports speakers fees and/or honoraria for advisory board membership of the following companies: AbbVie, Almirall, Apogee, Boehringer Ingelheim, BMS, Janssen, Leo, Lilly, Moonlake, Novartis, Sanofi, Sitryx, and UCB. Kilian Eyerich holds shares and is a co-founder of Dermagnostix and Dermagnostix R&D. David Ranzinger has no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: This study does not contain any personal data that require consent for publication.
: Not applicable.
: Not applicable.
: Both authors contributed equally to the conception, design, drafting, and critical revision of the manuscript. Both authors approved the final version.
